Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down - Should You Sell?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $15.55, but opened at $13.80. Y-mAbs Therapeutics shares last traded at $14.60, with a volume of 78,421 shares trading hands.

Wall Street Analysts Forecast Growth

YMAB has been the subject of several recent research reports. Canaccord Genuity Group reissued a "buy" rating and set a $26.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Wedbush reissued an "outperform" rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. Morgan Stanley dropped their price target on Y-mAbs Therapeutics from $12.00 to $11.00 and set an "underweight" rating for the company in a research report on Tuesday, August 13th. HC Wainwright reissued a "buy" rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Finally, Canaccord Genuity Group raised Y-mAbs Therapeutics to a "strong-buy" rating in a research report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $21.14.

Y-mAbs Therapeutics Stock Down 0.5 %

The firm has a fifty day moving average price of $14.08 and a 200-day moving average price of $13.17. The firm has a market cap of $689.94 million, a price-to-earnings ratio of -26.96 and a beta of 0.68.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its earnings results on Monday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. The firm had revenue of $22.80 million during the quarter, compared to analyst estimates of $23.09 million. During the same quarter in the previous year, the business posted ($0.14) EPS. Equities research analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.62 earnings per share for the current fiscal year.

Insider Activity at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 30,000 shares of Y-mAbs Therapeutics stock in a transaction on Monday, September 16th. The stock was sold at an average price of $12.97, for a total value of $389,100.00. Following the transaction, the insider now owns 67,681 shares in the company, valued at approximately $877,822.57. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Thomas Gad sold 30,000 shares of Y-mAbs Therapeutics stock in a transaction on Monday, September 16th. The stock was sold at an average price of $12.97, for a total value of $389,100.00. Following the transaction, the insider now owns 67,681 shares in the company, valued at approximately $877,822.57. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Joris Wilms sold 5,000 shares of Y-mAbs Therapeutics stock in a transaction on Monday, August 26th. The shares were sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the transaction, the chief operating officer now owns 30,600 shares in the company, valued at $449,514. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 100,000 shares of company stock worth $1,338,100. 22.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. lifted its stake in shares of Y-mAbs Therapeutics by 39.9% during the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company's stock worth $60,000 after purchasing an additional 1,056 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Y-mAbs Therapeutics by 8.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company's stock worth $345,000 after acquiring an additional 1,657 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Y-mAbs Therapeutics by 3.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company's stock worth $993,000 after acquiring an additional 2,760 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Y-mAbs Therapeutics by 66.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company's stock worth $113,000 after acquiring an additional 3,416 shares during the last quarter. Finally, Rice Hall James & Associates LLC increased its position in shares of Y-mAbs Therapeutics by 4.2% during the second quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company's stock worth $1,084,000 after acquiring an additional 3,589 shares during the last quarter. Institutional investors and hedge funds own 70.85% of the company's stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.